The US Food and Drug Administration (FDA) is seeking public comment on the controversial Commissioner’s National Priority Voucher (CNPV) pilot program.
The CNPV pilot program was established in June 2025 to address “critical public health needs” by providing an “ultra-fast” review pathway for drugs and biological products of strategic national importance
Register for free to keep reading
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day